ENDRA Life Sciences (NDRA) Financials

$6.10

$0.42 (7.39%)

As on 04-Sep-2026 16:00EDT

Market cap

$9 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.12	--	0.21	0.28	0.23	0.22
Gross Profit	-0.12	--	-0.21	-0.28	-0.23	-0.22
Operating Expenses	6.61	5.76	10.82	10.52	13.16	11.50
Operating Profit (EBIT)	-6.65	-5.76	-10.82	-10.52	-13.16	-11.50
Other Income	--	--	--	--	--	--
Profit before Tax	-5.92	-7.03	-11.51	-10.06	-13.18	-11.23
Provision for Tax	--	--	--	0.00	0.02	-0.04
Profit after Tax (Net Income)	-5.92	-7.03	-11.51	-10.06	-13.18	-11.23
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-13.18	-11.35

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	6.31	2.26	2.56	5.66	7.20	10.78
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.85	0.84	1.29	0.19	0.37	0.55
Current Liabilities	0.79	0.75	0.61	0.90	1.70	1.54
Total Liabilities	8.73	3.85	4.45	6.75	9.27	12.87

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	2.36	2.89	1.02	3.72	0.75	0.78
Current Assets	5.59	0.97	3.43	3.03	8.53	12.09
Total Assets	8.73	3.85	4.45	6.75	9.27	12.87
Total Debt*	0.43	0.49	0.75	0.39	0.55	0.80
Net Current Assets	4.80	0.22	2.83	2.13	6.82	10.55

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-5.18	-7.40	-9.55	-12.77	-11.12
Cash Flow from Investing Activities	--	-3.02	-0.01	-0.02	-0.20	-0.05
Cash from Financing Activities	--	5.73	7.81	7.52	8.40	13.40
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-7.15	-8.93	-21.51	-5.89	-6.83	-5.36
Cash EPS ($)	-6.29	-8.73	-21.13	-5.72	-6.71	-5.25
Adjusted Book Value ($)	4.21	2.87	4.79	3.31	3.73	5.15
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-6.59	-13.84	-5.59	-6.62	-5.31
Free Cash Flow per Share ($)	--	-6.61	-13.87	-5.61	-6.72	-5.33

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-231.66	-245.69	-145.75	-136.35	-115.08
ROE (%)	-138.08	-291.56	-280.02	-156.42	-146.53	-125.11
ROA (%)	-97.69	-169.21	-205.38	-125.53	-119.01	-103.80
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-375.65	38.93	-14.39	23.54	-17.15	2.28
Net Profit Growth (%)	32.50	38.93	-14.39	23.67	-17.34	4.22
EPS Growth (%)	46.71	0.58	-2.65	0.14	-0.27	0.45
Book Value Growth (%)	24.08	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.51	-0.29	-0.36	-0.60	-0.13
Price / Book Value	1.24	1.58	1.31	0.64	1.09	0.13
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.11	-0.48	-0.08	-0.12	-0.27	0.66
Close Price ($)	5.33	4.53	6.26	3,710.00	7,122.50	24,213.00
High Price ($)	11.96	11.96	3,396.75	9,432.50	27,650.00	108,500.00
Low Price ($)	2.96	2.90	4.01	1,522.50	5,528.25	24,153.50
Market Cap ($ Cr)	9.07	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.22	0.29	0.07	0.08	0.07
Short term debt to equity ratio	0.02	0.06	0.10	0.04	0.03	0.02
Current Ratio	7.10	1.29	5.67	3.36	5.00	7.83
Quick Ratio	7.10	--	--	0.45	3.45	7.00
Interest Coverage	--	--	--	--	-611.04	-42.06

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	4,646.61	3,492.43	3,063.24	1,525.19
Payable days	--	--	558.12	646.01	1,095.33	971.63
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.